GlassScriptPhysician profile
Romina A Kee
NPI 1326077579
$6,821.03
in general payments reported to CMS, 2019-2025
23 companies · $2,517 in 2025
The $2,517 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $231 · 2021: $317 · 2022: $465 · 2023: $1,535 · 2024: $1,755 · 2025: $2,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,807.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,789.39 | 2021-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $1,843.57 | 2020-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $703.13 | 2020-2025 | Pifeltro, Gardasil 9, Delstrigo |
| Janssen Biotech, INC. | $267.64 | 2020-2023 | Symtuza |
| Theratechnologies INC. | $221.34 | 2023-2025 | Trogarzo, Egrifta |
| Emd Serono, INC. | $163.53 | 2022-2024 | Serostim |
| Exact Sciences Corporation | $139.75 | 2024-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $126.04 | 2023 | Aptima |
| Organon LLC | $96.22 | 2023-2025 | Nexplanon |
| Coopersurgical, INC. | $87.77 | 2022 | |
| Napo Pharmaceuticals INC | $68.64 | 2024-2025 | Mytesi |
| Dynavax Technologies Corporation | $49.12 | 2021-2024 | Heplisav-B |
| Corium, LLC | $38.26 | 2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $35.41 | 2022-2023 | |
| Pfizer INC. | $26.66 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.04 | 2024 | Gvoke Hypopen |
| Noven Therapeutics, LLC | $23.46 | 2025 | Secuado |
| Otsuka America Pharmaceutical, INC. | $22.11 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $22.04 | 2023 | Invega Trinza, Invega Sustenna |
| Indivior INC. | $21.71 | 2024 | Perseris |
| Abbvie INC. | $19.33 | 2024 | |
| Braeburn INC. | $18.20 | 2025 | Brixadi |
| Lilly USA, LLC | $13.67 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romina Kee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.